

EDCTP Contract N^o RIA2020EF-2918



E D C T P



Rapid diagnostics for COVID-19: manufacturable in Africa to increase affordability, improve epidemic preparedness and strengthen local resilience

Deliverable report

Deliverable number	5.4
WP no/title	5/ Proof of Concept Serological Test Development Using Single - Chain Antibody Fragments (scFvs)
Deliverable title	Testing pre-screened clinical serum samples with AfriMx
Responsible partner	KNUST
Due date	Dec 2021 amended to May 2022
Actual submission date	Report: 20 May 2022 - Task unfinished

History of changes:

Date	Version no	Comments
20/5/2022	1.0	Status of deliverable : unfinished – see report

Delivery Type

R	Report	
DEM	Demonstrator, pilot, prototype, plan designs, new or revised health policies etc	✓
DEC	Websites, patents filing, press & media actions, etc	
OTHER	Other	

Dissemination Level

PU	Public	✓
RE	Restricted to a group specified by the consortium.	

List of content

1 STATUS OF THE DELIVERABLE 2

2 SUMMARY OF THE RESULTS (MAX. 1-2 PAGES)..... 2

3 DESCRIPTION OF WORK PERFORMED AND OBTAINED RESULTS 2

3.1 PLEASE USE NUMBERED SUBSECTIONS **ERROR! BOOKMARK NOT DEFINED.**

Partner	Contribution to this deliverable
UCAM	Design and engineer of the scFVs. Production of scFv constructs ready for transfer to KNUST
KNUST	Ready for next stage of production.

1 Status of the Deliverable

The original proposal explored the potential of the scFvs and antigens generated in D5.1 and D5.2 as forming the basis of a routine screening assay either/or ELISA /lateral flow test. This aspect was proposed as an ambitious goal within the overall project. In D5.3, the SOP for production was further developed ready for transfer to Ghana. However, the delays with the NAT clinical trial (described in other WPs) put the immunoassay behind and towards the end of the project, there was a fall off in available samples.

This deliverable has not been completed.

2 Summary of the results

As a result of successful completion of D5.1, D5.2 and D5.3, we are now in a position to develop these assays in Ghana. Importantly, this work will now be able to continue as part of a project we have established in collaboration with NMIMR and Dr Kofi Bon (funded by Royal Society UK).

3 Description of work performed and obtained results

In the time available, all the basic components for assay development are now in place and these are now being used for further development of LF and ELISA based assays.